Scientists have discovered distinctive immune markers in blood samples that appear years before inflammatory bowel disease develops, according to findings presented at UEG Week 2026. Inflammatory bowel disease encompasses chronic digestive tract conditions including Crohn’s disease and ulcerative colitis, which occur when the immune system responds abnormally. While researchers have suspected that IBD begins developing long before clinical diagnosis, the specific immune changes occurring during this early phase have remained largely unclear.
To understand these early immune alterations, investigators analyzed blood serum from 500 participants collected at multiple time points spanning up to 10 years before diagnosis. The group included individuals who developed Crohn’s disease, those who developed ulcerative colitis, and healthy controls. Researchers examined antibody responses to approximately 357,000 different antigens derived from bacteria, viruses, food, and the immune system itself, ultimately identifying over 123,000 unique antibodies across all samples.
Key differences emerged between groups. Individuals who later developed IBD showed significantly reduced antibody diversity compared to healthy participants. Additionally, Crohn’s disease and ulcerative colitis were associated with distinct immune signatures. Those developing Crohn’s disease exhibited elevated antibody responses to herpesviruses and bacterial flagellin, particularly those who went on to develop complicated disease. Meanwhile, people who developed ulcerative colitis displayed increased antibody responses to herpesviruses and autoantigens, which are components of the body’s own tissues.
Using machine learning analysis, researchers determined that these antibody patterns could effectively distinguish future IBD cases from healthy individuals. For Crohn’s disease, the predictive model achieved an area under the curve score of 0.90, while ulcerative colitis reached 0.84. The researchers also found that antibody profiles could identify approximately 10 years before diagnosis which patients would develop complicated Crohn’s disease, with a score of 0.85.
Despite the promising results, researchers emphasized that the findings require substantial additional validation before clinical implementation. Future studies must confirm these patterns in larger, more diverse populations, establish added value beyond existing genetic and clinical assessments, and demonstrate that such testing ultimately improves patient outcomes. Lead researcher Dr. Arno Bourgonje stated that next priorities include validating signatures in independent populations and translating findings into reproducible, affordable screening assays.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI